Citation only
via Europe PMC
Investigating the efficacy and toxicity of partial <i>in vivo</i> reprogramming as a rejuvenation intervention.
Meiners F, Palmer D, Avelar RA, Barrantes I, Fuellen G.
Aging · 2026
Genomic instability
Stem-cell exhaustion
Altered intercellular communication
Chronic inflammation
Partial reprogramming (OSK)
Mouse
Abstract
Partial reprogramming(definition) by cyclic expression of Yamanaka factors has been proposed as a rejuvenation strategy, yet evaluating tissue-specific responses and potential risks remains challenging. Here, we reanalyzed RNA-seq data from the liver, kidney, and spleen of aged mice subjected to seven months of partial reprogramming. We used the Adverse Outcome Pathway (AOP) framework to estimate adverse and beneficial signatures, assessed functional changes via gene set enrichment analysis and deconvoluted bulk RNA-seq data to estimate differences in cell type proportion. In the liver and kidney, partial reprogramming suppressed age-activated immune and inflammatory processes, while activating age-suppressed metabolic and catabolic pathways. In the spleen, cell cycle, DNA replication, and DNA damage response programs were prominent, indicative of increased proliferative activity, and cell type deconvolution showed increased proportions of megakaryocyte-erythroid progenitor cells and decreased proportions of natural killer cells, while AOPs flagged a potential risk of sustained genomic and proliferative stress. Based on the existing AOP framework, we did not find any enriched Key Events in the kidney (reprogrammed vs. old). In the liver, AOP analysis identified pathways regulated in opposition to liver steatosis, indicated by activation of nuclear receptor signaling (<i>Ppara, Pparg</i>) and restoration of fatty-acid oxidation and metabolism. Our findings highlight tissue-specific responses to partial reprogramming and emphasize the need for larger, controlled studies to clarify physiological outcomes and safety.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.18632/aging.206431
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
F, M., D, P., RA, A., I, B., & G., F. (2026). Investigating the efficacy and toxicity of partial <i>in vivo</i> reprogramming as a rejuvenation intervention. <em>Aging</em>. https://doi.org/10.18632/aging.206431
Vancouver
F M, D P, RA A, I B, G. F. Investigating the efficacy and toxicity of partial <i>in vivo</i> reprogramming as a rejuvenation intervention. Aging. 2026. doi:10.18632/aging.206431.
BibTeX
@article{meiners2026Invest,
title = {Investigating the efficacy and toxicity of partial <i>in vivo</i> reprogramming as a rejuvenation intervention.},
author = {Meiners F and Palmer D and Avelar RA and Barrantes I and Fuellen G.},
journal = {Aging},
year = {2026},
doi = {10.18632/aging.206431},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging 2026
Open access · CC-BY
Investigating the efficacy and toxicity of partial in vivo reprogramming as a rejuvenation intervention
The FASEB Journal 2020
Citation only
Effect of senolytic treatment on expression of senescence‐associated miR‐126 expression in young and old female mice.
European Heart Journal 2021
Open access · OA
DNA damage and extranuclear DNA sensors: a dangerous duo in atherosclerosis
Nucl. Saf.; (United States) 1977
Citation only
Common-mode failures in reactor safety systems
Cell and Tissue Banking 2023
Citation only
Bone marrow mesenchymal stem cells’ osteogenic potential: superiority or non-superiority to other sources of mesenchymal stem cells?
Aging Cell 2020
Open access · CC-BY